{"id":"NCT02553317","sponsor":"Ablynx, a Sanofi company","briefTitle":"Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura","officialTitle":"A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-08","completion":"2017-08","firstPosted":"2015-09-17","resultsPosted":"2019-05-22","lastUpdate":"2023-04-05"},"enrollment":145,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Thrombotic Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Caplacizumab","otherNames":["ALX-0081"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":["ALX-0081 Placebo"]}],"arms":[{"label":"Caplacizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis","primaryOutcome":{"measure":"Time to Platelet Count Response","timeFrame":"Only data from the DB daily PE period (median = 5 days) up to the cut-off were used. The cut-off point was defined by whichever occured first: 1) 45 days of daily PE after start of study drug, 2) stop of daily PE, 3) stop of study drug (median = 34 days)","effectByArm":[{"arm":"Caplacizumab","deltaMin":2.69,"sd":null},{"arm":"Placebo","deltaMin":2.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0099"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":101,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Netherlands","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["33881463","31691462","30625070"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":71},"commonTop":["Epistaxis","Headache","Hypokalemia","Nausea","Catheter site hemorrhage"]}}